Gujarat Fluorochemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 29, 2025, 9:00 pm

Quick Insight

Gujarat Fluorochemicals Ltd, with a current share price of ₹3,801 and a market capitalization of ₹41,757 Cr., exhibits a relatively high Price-to-Earnings (P/E) ratio of 67.1. This valuation metric surpasses the sector average in India, which typically hovers around 20-30x. The company's Return on Equity (ROE) of 8.29% and Return on Capital Employed (ROCE) of 9.89% indicate moderate profitability levels, with room for improvement compared to industry peers. Additionally, Gujarat Fluorochemicals' Operating Profit Margin (OPM) of 27% is robust, reflecting efficient cost management in its operations.

One key strength of Gujarat Fluorochemicals is its healthy balance sheet, with reserves amounting to ₹7,242 Cr. This provides a solid financial cushion for the company's operations and expansion plans. However, the firm's high Price-to-Book Value (P/BV) ratio of 5.73x suggests the stock may be overvalued compared to its intrinsic worth. Furthermore, the extended Cash Conversion Cycle (CCC) of 418 days poses a risk in terms of liquidity management and working capital efficiency. Looking ahead, a scenario where Gujarat Fluorochemicals focuses on reducing its CCC and enhancing its ROE and ROCE could potentially boost investor confidence and drive stock performance.

In conclusion, while Gujarat Fluorochemicals demonstrates strengths in profitability and balance sheet health, investors should carefully monitor the company's operational efficiency and valuation metrics. By addressing liquidity concerns and enhancing profitability ratios, the company could position itself more competitively within the sector, offering potential upside for shareholders in the long run.

Competitors of Gujarat Fluorochemicals Ltd

All Competitor Stocks of Gujarat Fluorochemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 10:00 am

Below is a detailed analysis of the quarterly data for Gujarat Fluorochemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,225.00 Cr. (Mar 2025) to 1,281.00 Cr., marking an increase of 56.00 Cr..
• For Expenses, as of Jun 2025, the value is 937.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 919.00 Cr. (Mar 2025) to 937.00 Cr., marking an increase of 18.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 344.00 Cr.. The value appears strong and on an upward trend. It has increased from 306.00 Cr. (Mar 2025) to 344.00 Cr., marking an increase of 38.00 Cr..
• For OPM %, as of Jun 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 25.00% (Mar 2025) to 27.00%, marking an increase of 2.00%.
• For Other Income, as of Jun 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
• For Interest, as of Jun 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 90.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 89.00 Cr. (Mar 2025) to 90.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 217.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 30.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 12.00% (Mar 2025) to 26.00%, marking an increase of 14.00%.
• For Net Profit, as of Jun 2025, the value is 184.00 Cr.. The value appears to be declining and may need further review. It has decreased from 191.00 Cr. (Mar 2025) to 184.00 Cr., marking a decrease of 7.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 16.75. The value appears to be declining and may need further review. It has decreased from 17.39 (Mar 2025) to 16.75, marking a decrease of 0.64.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:45 pm

Growth

Last Updated: September 5, 2025, 5:35 am

Balance Sheet

Last Updated: July 25, 2025, 3:08 pm

Below is a detailed analysis of the balance sheet data for Gujarat Fluorochemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
• For Reserves, as of Mar 2025, the value is 7,242.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,925.00 Cr. (Mar 2024) to 7,242.00 Cr., marking an increase of 1,317.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2,080.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,096.00 Cr. (Mar 2024) to 2,080.00 Cr., marking a decrease of 16.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,276.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,201.00 Cr. (Mar 2024) to 1,276.00 Cr., marking an increase of 75.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 10,609.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,233.00 Cr. (Mar 2024) to 10,609.00 Cr., marking an increase of 1,376.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4,329.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,264.00 Cr. (Mar 2024) to 4,329.00 Cr., marking an increase of 65.00 Cr..
• For CWIP, as of Mar 2025, the value is 1,524.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,128.00 Cr. (Mar 2024) to 1,524.00 Cr., marking an increase of 396.00 Cr..
• For Investments, as of Mar 2025, the value is 290.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 290.00 Cr., marking an increase of 289.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,466.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,840.00 Cr. (Mar 2024) to 4,466.00 Cr., marking an increase of 626.00 Cr..
• For Total Assets, as of Mar 2025, the value is 10,609.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,233.00 Cr. (Mar 2024) to 10,609.00 Cr., marking an increase of 1,376.00 Cr..

Notably, the Reserves (7,242.00 Cr.) exceed the Borrowings (2,080.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gujarat Fluorochemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 39.60. This value is within the healthy range. It has decreased from 120.44 (Mar 23) to 39.60, marking a decrease of 80.84.
• For Diluted EPS (Rs.), as of Mar 24, the value is 39.60. This value is within the healthy range. It has decreased from 120.44 (Mar 23) to 39.60, marking a decrease of 80.84.
• For Cash EPS (Rs.), as of Mar 24, the value is 65.64. This value is within the healthy range. It has decreased from 141.93 (Mar 23) to 65.64, marking a decrease of 76.29.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 540.40. It has increased from 502.57 (Mar 23) to 540.40, marking an increase of 37.83.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 540.40. It has increased from 502.57 (Mar 23) to 540.40, marking an increase of 37.83.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 389.70. It has decreased from 517.49 (Mar 23) to 389.70, marking a decrease of 127.79.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 92.33. This value is within the healthy range. It has decreased from 194.59 (Mar 23) to 92.33, marking a decrease of 102.26.
• For PBIT / Share (Rs.), as of Mar 24, the value is 66.29. This value is within the healthy range. It has decreased from 173.10 (Mar 23) to 66.29, marking a decrease of 106.81.
• For PBT / Share (Rs.), as of Mar 24, the value is 54.17. This value is within the healthy range. It has decreased from 162.47 (Mar 23) to 54.17, marking a decrease of 108.30.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 39.60. This value is within the healthy range. It has decreased from 120.44 (Mar 23) to 39.60, marking a decrease of 80.84.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 39.60. This value is within the healthy range. It has decreased from 120.97 (Mar 23) to 39.60, marking a decrease of 81.37.
• For PBDIT Margin (%), as of Mar 24, the value is 23.69. This value is within the healthy range. It has decreased from 37.60 (Mar 23) to 23.69, marking a decrease of 13.91.
• For PBIT Margin (%), as of Mar 24, the value is 17.01. This value is within the healthy range. It has decreased from 33.45 (Mar 23) to 17.01, marking a decrease of 16.44.
• For PBT Margin (%), as of Mar 24, the value is 13.90. This value is within the healthy range. It has decreased from 31.39 (Mar 23) to 13.90, marking a decrease of 17.49.
• For Net Profit Margin (%), as of Mar 24, the value is 10.16. This value exceeds the healthy maximum of 10. It has decreased from 23.27 (Mar 23) to 10.16, marking a decrease of 13.11.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 10.16. This value is within the healthy range. It has decreased from 23.37 (Mar 23) to 10.16, marking a decrease of 13.21.
• For Return on Networth / Equity (%), as of Mar 24, the value is 7.32. This value is below the healthy minimum of 15. It has decreased from 24.06 (Mar 23) to 7.32, marking a decrease of 16.74.
• For Return on Capital Employeed (%), as of Mar 24, the value is 10.81. This value is within the healthy range. It has decreased from 31.52 (Mar 23) to 10.81, marking a decrease of 20.71.
• For Return On Assets (%), as of Mar 24, the value is 4.71. This value is below the healthy minimum of 5. It has decreased from 15.87 (Mar 23) to 4.71, marking a decrease of 11.16.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 23) to 0.06, marking an increase of 0.03.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.33. This value is within the healthy range. It has increased from 0.26 (Mar 23) to 0.33, marking an increase of 0.07.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.48. It has decreased from 0.74 (Mar 23) to 0.48, marking a decrease of 0.26.
• For Current Ratio (X), as of Mar 24, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.50 (Mar 23) to 1.36, marking a decrease of 0.14.
• For Quick Ratio (X), as of Mar 24, the value is 0.73. This value is below the healthy minimum of 1. It has decreased from 0.86 (Mar 23) to 0.73, marking a decrease of 0.13.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.52. This value is below the healthy minimum of 4. It has decreased from 2.61 (Mar 23) to 1.52, marking a decrease of 1.09.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 5.05. This value is below the healthy minimum of 20. It has increased from 3.30 (Mar 23) to 5.05, marking an increase of 1.75.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.04. This value is below the healthy minimum of 20. It has increased from 2.80 (Mar 23) to 3.04, marking an increase of 0.24.
• For Earning Retention Ratio (%), as of Mar 24, the value is 94.95. This value exceeds the healthy maximum of 70. It has decreased from 96.70 (Mar 23) to 94.95, marking a decrease of 1.75.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.96. This value exceeds the healthy maximum of 70. It has decreased from 97.20 (Mar 23) to 96.96, marking a decrease of 0.24.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 7.62. This value is within the healthy range. It has decreased from 18.30 (Mar 23) to 7.62, marking a decrease of 10.68.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 4.27. This value is within the healthy range. It has decreased from 12.33 (Mar 23) to 4.27, marking a decrease of 8.06.
• For Enterprise Value (Cr.), as of Mar 24, the value is 35,822.28. It has increased from 34,443.07 (Mar 23) to 35,822.28, marking an increase of 1,379.21.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 8.37. This value exceeds the healthy maximum of 3. It has increased from 6.06 (Mar 23) to 8.37, marking an increase of 2.31.
• For EV / EBITDA (X), as of Mar 24, the value is 35.32. This value exceeds the healthy maximum of 15. It has increased from 16.11 (Mar 23) to 35.32, marking an increase of 19.21.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 7.95. This value exceeds the healthy maximum of 3. It has increased from 5.83 (Mar 23) to 7.95, marking an increase of 2.12.
• For Retention Ratios (%), as of Mar 24, the value is 94.94. This value exceeds the healthy maximum of 70. It has decreased from 96.69 (Mar 23) to 94.94, marking a decrease of 1.75.
• For Price / BV (X), as of Mar 24, the value is 5.73. This value exceeds the healthy maximum of 3. It has decreased from 6.00 (Mar 23) to 5.73, marking a decrease of 0.27.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 7.95. This value exceeds the healthy maximum of 3. It has increased from 5.83 (Mar 23) to 7.95, marking an increase of 2.12.
• For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.01, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness